Inhibition of Transglutaminase 2 by a Selective Small Molecule Inhibitor Reduces Fibrosis and Improves Pulmonary Function in a Bleomycin Mouse Model
Cells · 26.03.2025 · 14 (7) · 497
DOI: 10.3390/cells14070497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 26.03.2025. Verfasst von Zhuo Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biosciences, College of Health and Life Sciences, Aston Triangle, Aston University, Birmingham B4 7ET, UK. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Transglutaminases, Lung, GTP-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Isterian Biotech Inc, research collaboration project with Isterian Biotech.
Abstract (Originalsprache)
This paper investigates the ability of our selective small molecule TG2 inhibitor 1-155 in reducing fibrosis in a bleomycin-induced pulmonary fibrosis mouse model. Formulated as a fine stable suspension, 1-155 was delivered intranasally (IN) at 3 mg/kg via IN delivery once daily. It significantly inhibited collagen deposition in the lungs in the bleomycin-challenged mice. Compared to its vehicle control treatment, a significant reduction in a key myofibroblast marker α smooth muscle actin and TG2 was also detected in the 1-155-treated animals. Most importantly, 1-155 treatment significantly improved several key lung function parameters, such as cord compliance, vital capacity, and dynamic compliance, which are comparable to that found for the positive control nintedanib at a much higher dosage of 60 mg/kg twice daily via oral delivery. The 1-155-treated mice showed a trend in improvement of average body weight. For the first time, our study demonstrates the effectiveness of a selective small molecule TG2 inhibitor in reducing pulmonary fibrosis in a pre-clinical model. Importantly, we were able to correlate this effect of 1-155 with the improvement of animal lung function showing the potential of the use of TG2 inhibitors as a therapeutic treatment for fibrotic lung conditions like IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biosciences, College of Health and Life Sciences, Aston Triangle, Aston University, Birmingham B4 7ET, UK.
- Isterian Biotech, Inc., 228 Park Ave S, #66643, New York, NY 10003, USA.
ORCID-Profile: Zoe Gale
Förderung
- Isterian Biotech Inc
- research collaboration project with Isterian Biotech
Zitieren
APA
Wang, Z., Sriram, S., Ugwoke, C., Gale, Z., Tabrizi, M., & Griffin, M. (2025). Inhibition of Transglutaminase 2 by a Selective Small Molecule Inhibitor Reduces Fibrosis and Improves Pulmonary Function in a Bleomycin Mouse Model. Cells, 14(7), 497. https://doi.org/10.3390/cells14070497
Vancouver
Wang Z, Sriram S, Ugwoke C, Gale Z, Tabrizi M, Griffin M. Inhibition of Transglutaminase 2 by a Selective Small Molecule Inhibitor Reduces Fibrosis and Improves Pulmonary Function in a Bleomycin Mouse Model. Cells. 2025;14(7):497. doi:10.3390/cells14070497
BibTeX
@article{Wang2025,
author = {Wang, Zhuo and Sriram, Sriniwas and Ugwoke, Cynthia and Gale, Zoe and Tabrizi, Maral and Griffin, Martin},
title = {Inhibition of Transglutaminase 2 by a Selective Small Molecule Inhibitor Reduces Fibrosis and Improves Pulmonary Function in a Bleomycin Mouse Model},
journal = {Cells},
year = {2025},
volume = {14},
number = {7},
pages = {497},
doi = {10.3390/cells14070497}
}
EUVIMED